{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Tharimmune, Inc. overvalued or undervalued?
As of October 15, 2023, Tharimmune, Inc. is considered an attractive investment due to its undervaluation, with a P/E ratio of 15.2 and a P/B ratio of 1.8, both lower than its peers, and its stock performance has outperformed the Sensex.
Is Tharimmune, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Tharimmune, Inc. to determine if it is bullish or bearish.
What does Tharimmune, Inc. do?
Tharimmune, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $2.78 million. Key metrics include a debt equity ratio of 0.56 and a return on equity of 1,248.32%.
How big is Tharimmune, Inc.?
As of Jun 18, Tharimmune, Inc. has a market capitalization of 2.78 million, with net sales of 0.00 million and a net profit of -12.49 million over the last four quarters. The company's shareholder's funds are 1.31 million, and total assets are 3.72 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
